SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥142.01-CN¥0.88 (-0.62%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.2% below the high.
Loading market information…
HKSE · 1763.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:08 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
China Isotope & Radiation Corporation’s quoted price sits in the lower half of its reported 52-week range, 53.04% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
China Isotope & Radiation Corporation’s forward annual dividend is HK$0.47 per share, paid quarterly. The forward yield is 3.97% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
China Isotope & Radiation Corporation’s next earnings report is currently expected on Mar 31, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow China Isotope & Radiation Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
China Isotope & Radiation Corporation is dedicated to the development, production, and distribution of diagnostic and therapeutic radiopharmaceuticals, as well as radioactive source products for both medical and industrial applications throughout China. The company's operations are divided into five principal areas. Its Pharmaceuticals division focuses on creating and marketing imaging diagnostic and therapeutic radiopharmaceuticals, UBT kits and analyzers, and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment furnishes medical and industrial radioactive sources, along with associated technical support services. The Irradiation segment offers sterilization services for products such as medical devices, food, traditional Chinese medicine, and cosmetics, in addition to providing engineering, procurement, and construction (EPC) services for gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment handles the sale of radiation therapy equipment and its corresponding maintenance. Finally, the Independent Clinical Medical and Laboratory Services, and Other Business segment delivers independent clinical laboratory services to hospitals and other medical institutions, covering a range of conditions including hepatitis, endocrine disorders, bone metabolism issues, cardiovascular diseases, and diabetes. Founded in 1983, the company's main office is located in Beijing, China, and it operates as a subsidiary of China National Nuclear Corporation.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:06 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Apr 26, 2023 |
| HK$1.00-38.65% vs estimate |
| HK$4.02B+11.86% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥142.01-CN¥0.88 (-0.62%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.2% below the high.
CN¥48.46-CN¥0.16 (-0.33%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.39% below the high.
HK$50.70+HK$0.05 (+0.1%)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 37.37% below the high.
CN¥181.75+CN¥2.75 (+1.54%)
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 16.2% below the high.
HK$32.36-HK$0.72 (-2.18%)
Hansoh Pharmaceutical Group Company Limited’s quoted price sits in the lower half of its reported 52-week range, 26.82% below the high.
HK$44.48-HK$0.58 (-1.29%)
WuXi Biologics (Cayman) Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.31% below the high.
HK$79.75-HK$1.85 (-2.27%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.24% below the high.
HK$38.10+HK$2.12 (+5.89%)
JD Health International Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.86% below the high.
